High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma

STAT3 Inhibition Is a Therapeutic Strategy for ABC-like Diffuse Large B-Cell Lymphoma

(2011) A. Scuto et al.   CANCER RESEARCH

Generation of diffuse large B cell lymphoma-associated antigen-specific Vα6/Vβ13+T cells by TCR gene transfer

(2011) Qingsong Yin et al.   Journal of Hematology & Oncology

Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma

(2010) F. Baran-Marszak et al.   HAEMATOLOGICA

Targeted therapy in lymphoma

(2010) Patrick B Johnston et al.   Journal of Hematology & Oncology

Regulation of the IL-23 and IL-12 Balance by Stat3 Signaling in the Tumor Microenvironment

(2009) Marcin Kortylewski et al.   CANCER CELL

IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway

(2009) Lin Wang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside

(2009) Jianbiao Zhou et al.   Journal of Hematology & Oncology

Stat3 mediates myeloid cell–dependent tumor angiogenesis in mice

(2008) Maciej Kujawski et al.   JOURNAL OF CLINICAL INVESTIGATION

Cancer-related inflammation

(2008) Alberto Mantovani et al.   NATURE

Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor- B pathways in subtypes of diffuse large B-cell lymphoma

(2007) L. T. Lam et al.   BLOOD

STAT3: A critical transcription activator in angiogenesis

(2007) Zhong Chen et al.   MEDICINAL RESEARCH REVIEWS